Osteoporosis, increasingly prevalent among the aging population, poses a global health challenge. Current treatments, often limited by prolonged treatment durations, serious side effects, and suboptimal efficacy, necessitate innovative approaches. Building on previous research that highlighted the rejuvenating potential of young blood in organ vitality. This study focused on the role of exosomes and exosomal miRNA. Specifically, we investigated the efficacy of exosomes derived from young plasma (Y-Exos) in mitigating osteoporosis, contrasting them with exosomes from aged plasma (A-Exos). Our analysis involved co-culturing bone marrow mesenchymal stem cells (BMSCs) with Y-Exos or A-Exos, assessing their impact on BMSCs migration, proliferation, and osteogenic differentiation. Y-Exos exhibited a marked enhancement in BMSCs proliferation, migration, and osteogenic differentiation compared to A-Exos. Corresponding studies corroborated these findings, demonstrating that Y-Exos significantly alleviated osteoporosis, whereas A-Exos impeded bone regeneration. Furthermore, our research identified exosomal miR-217–5p as a pivotal contributor to the osteoprotective effects of Y-Exos. Our work provided a potential strategy for advancing the clinical treatment of osteoporosis.

中文翻译：

---

来自年轻血浆的外泌体通过miR-217-5p调节骨髓间充质干细胞的成骨作用缓解骨质疏松

骨质疏松症在老龄化人口中日益普遍，构成了全球健康挑战。目前的治疗方法通常受到治疗持续时间长、副作用严重和疗效欠佳的限制，因此需要创新的方法。之前的研究强调了年轻血液在器官活力方面的恢复潜力。本研究重点关注外泌体和外泌体 miRNA 的作用。具体来说，我们研究了源自年轻血浆的外泌体（Y-Exos）在减轻骨质疏松症方面的功效，并将其与源自老年血浆的外泌体（A-Exos）进行了对比。我们的分析涉及将骨髓间充质干细胞 (BMSC) 与 Y-Exos 或 A-Exos 共培养，评估它们对 BMSC 迁移、增殖和成骨分化的影响。与 A-Exos 相比，Y-Exos 在 BMSC 增殖、迁移和成骨分化方面表现出显着增强。相应的研究证实了这些发现，表明 Y-Exos 显着减轻骨质疏松症，而 A-Exos 阻碍骨再生。此外，我们的研究发现外泌体 miR-217-5p 是 Y-Exos 骨保护作用的关键贡献者。我们的工作为推进骨质疏松症的临床治疗提供了潜在的策略。